Effects of sildenafil on the human response to acute hypoxia and exercise

High Altitude Medicine and Biology

Volumn 6, Issue 1, 2005, Pages 43-49

  Ricart, Antoni ^a,c   Maristany, Jaume ^a   Fort, Núria ^b   Leal, Conxita ^c   Pagés, Teresa ^b   Viscor, Ginés ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Inst d'Estudis de Med de Muntanya   (Spain)

Author keywords

5 phosphodiesterase; High altitude; High altitude pulmonary edama; Hypobaric chamber; Pulmonary hypertension; Pulmonary vasoconstriction

Indexed keywords

OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL;

ACUTE DISEASE; ADULT; ALTITUDE; ARTERIAL OXYGEN SATURATION; ARTICLE; BREATHING RATE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; EXERCISE; EXPOSURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPOBARISM; HYPOXIA; LUNG ARTERY PRESSURE; LUNG VENTILATION; MALE; OXYGEN TRANSPORT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT PARAMETERS; REST; SIMULATION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TIDAL VOLUME;

ACUTE DISEASE; ADULT; ALTITUDE; ANOXIA; BLOOD PRESSURE; CARDIAC OUTPUT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TOLERANCE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PULMONARY CIRCULATION; REFERENCE VALUES; TIDAL VOLUME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 17344362498     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2005.6.43     Document Type: Article

References (29)

1. Anand I.S., Prasad B.A., Chugh S.S., Rao K.R., Cornfield D.N., Milla C.E., Singh N., Singh S., and Selvamurthy W. (1998). Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. Circulation 98: 2441-2445.
2. Antezana A.M., Antezana G., Aparicio O., Noriega I., Velarde F.L., and Richalet J.P. (1998). Pulmonary hypertension in high-altitude chronic hypoxia: Response to nifedipine. Eur. Respir. J. 12:1181-1185.
3. Bartsch P. (1999). High altitude pulmonary edema. Med. Sci. Sports Exerc. 31:S23-S27.
4. Bartsch P., Maggiorini M., Ritter M., Noti C., Vock P., and Oelz O. (1991). Prevention of high-altitude pulmonary edema by nifedipine. N. Engl. J. Med. 325:1284-1289.
5. Bartsch P., Swenson E.R., and Maggiorini M. (2001). Up-date: High altitude pulmonary edema. Adv. Exp. Med. Biol. 502:89-106.
6. Bossone E., Avelar E., Bach D.S., Gillespie B., Rubenfire M., and Armstrong W.F. (2000). Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters for the detection of exercise induced pulmonary arterial hypertension. Int. J. Card. Imaging 16:429-436.
7. Busch T., Bartsch P., Pappert D., Grunig E., Hildebrandt W., Elser H., Falke K.J., and Swenson E.R. (2001). Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am. J. Respir. Crit Care Med. 163:368-373.
8. Droma Y., Hanaoka M., Ota M., Katsuyama Y., Koizumi T., Fujimoto K., Kobayashi T., and Kubo K. (2002). Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 106:826-830.
9. Duplain H., Sartori C., Lepori M., Egli M., Allemann Y., Nicod P., and Scherrer U. (2000). Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am. J. Respir. Crit. Care Med. 162:221-224.
10. Hackett P., and Rennie D. (2002). High-altitude pulmonary edema. JAMA 287:2275-2278.
11. Hackett P.H., Roach R.C., Hartig G.S., Greene E.R., and Levine B.D. (1992). The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: A comparison. Int. J. Sports Med. 13 Suppl. 1:S68-S71.
12. Harzbecker K. (1985). [Effects of various forms of hypoxia and physical stress on pulmonary circulation. Z. Erkr. Atmungsorgane. 164:280-283.
13. Hultgren H.N. (1997). High altitude pulmonary edema: Hemodynamic aspects. Int. J. Sports Med. 18:20-25.
14. Jackson G., Benjamin N., Jackson N., and Allen M.J. (1999). Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol. 83:13C-20C.
15. Kennedy T., and Summer W. (1982). Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. Am. J. Cardiol. 50:864-868.
16. Kennedy T.P., Michael J.R., and Summer W. (1985). Calcium channel blockers in hypoxic pulmonary hypertension. Am. J. Med. 78:18-26.
17. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. (2002). Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105:2398-2403.
18. Oelz O., Maggiorini M., Ritter M., Noti C., Waber U., Vock P., and Bartsch P. (1992). Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int. J. Sports Med. 13 Suppl. 1:S65-S68.
19. Oelz O., Noti C., Ritter M., Jenni R., and Bartsch P. (1991). Nifedipine for high altitude pulmonary oedema. Lancet 337:556.
20. Packer M. (1985). Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am. J. Cardiol. 55:196B-201B.
21. Sartori C., Allemann Y., Trueb L., Lepori M., Maggiorini M., Nicod P., and Scherrer, U. (2000). Exaggerated pulmonary hypertension is not sufficient to trigger high-altitude pulmonary oedema in humans. Schweiz. Med. Wochenschr. 130:385-389.
22. Scherrer U., Vollenweider L., Delabays A., Savcic M., Eichenberger U., Kleger G.R., Fikrle A., Ballmer P.E., Nicod P., and Bartsch P. (1996). Inhaled nitric oxide for high-altitude pulmonary edema. N. Engl. J. Med. 334:624-629.
23. SoRelle R. (2002). Endothelial nitric oxide synthase gene polymorphisms at heart of high-altitude pulmonary edema. Circulation 106:e9013-e9014.
24. Swenson E.R., Maggiorini M., Mongovin S., Gibbs J.S., Greve I., Mairbaurl H., and Bartsch P. (2002). Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA 287:2228-2235.
25. Voelkel N.F. (2002). High-altitude pulmonary edema. N. Engl. J. Med. 346:1606-1607.
26. Watt M., Peacock A.J., Newell J., McDonagh T., and Grant S. (2000). The effect of amlodipine on respiratory and pulmonary vascular responses to hypoxia in mountaineers. Eur. Respir. J. 15:459-463.
27. Weiss J., Haefeli W.E., Gasse C., Hoffmann M.M., Weyman J., Gibbs S., Mansmann U., and Bartsch P. (2003). Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt. Med. Biol. 4:355-366.
28. Wilkins M.R., Aldashev A., and Morrell N.W. (2002). Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions. Lancet 359:1539-1540.
29. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., Mirrakhimov M.M., Aldashev A., and Wilkins M.R. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424-428.